DRMA Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Dermata Therapeutics Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerDRMA

Market Cap5.4M

Cash RunwayRunway 6-12 months

Next Catalystn/a

Public Research Snapshot

Dermata Therapeutics Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for DMT310 in Acne Vulgaris (Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
DMT310	Acne Vulgaris	n/a	Phase 3	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT06090721	Phase 3	COMPLETED	520	2025-03-31

Scientific Context

asset_name | DMT310
asset_name | DMT310
asset_name | DMT310
asset_name | DMT310
asset_name | DMT310

Want the full DRMA research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.